

REMARKS

Claims 17, 21 and 22 have been cancelled. Claims 3, 4, 5, 7, 8, 9, 11, 18 and 20 have been amended. These amendments are not intended to abandon, disclaim or dedicate any subject matter.

The amendments to the specification has been made to make of record any cross reference. The abstract has also been amended. Accordingly, Applicants submit no new matter by these amendments.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".


In the unlikely event that the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 251502007500.

PLEASE DO NOT CHARGE THE FILING FEES. APPLICANTS WILL PAY FILING FEES WITH RESPONSE TO NOTICE TO FILE MISSING PARTS.

Respectfully submitted,

Dated: January 25, 2002

By:



Gladys H. Monroy
Registration No. 32,430

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5711
Facsimile: (650) 494-0792

In the Claims:

Please amend the following claims

3. (Amended) A compound according to claim 1 [or claim 2]wherein R² and R³ independently represent a C₁-C₅ alkyl group, a C₃₋₁₀ cycloalkyl group, or a group of formula




wherein n is 0, 1 or 2 and R⁶ represents an unsubstituted or substituted phenyl or pyridyl group.

4. (Amended) A compound according to [any one of]claim[s] 1[to 3] wherein R¹ is a methyl, ethyl, propyl, pyridyl, pyridylmethyl, benzyl or *N*-morpholinylmethyl group; R² is an ethyl, propyl, n-butyl, i-butyl, n-pentyl, methoxyethyl, substituted or unsubstituted benzyl or 3-pyridylmethyl group; and R³ is an ethyl, propyl or n-butyl group.

5. (Amended) A compound according to [any one of]claim[s] 1[to 4] wherein the ring formed by R⁴, R⁵ and the nitrogen atom to which they are attached is a piperidyl, piperazinyl, [1,4]diazepan-1-yl, morpholinyl, pyrazolyl, azetidyl, diazabicyclo[2.2.1]hept-2-yl or hexahydro-pyrrolo[1,2-a] pyrazinyl group which is unsubstituted or substituted by one or more groups selected from a C₁-C₄ alkyl, C₂-C₄ alkenyl, carbamoyl, amino, di-C₁-C₄-alkylamino, (2-hydroxyethyl)methylamino, hydroxyl, 2,2,2-trifluoroethanoyl, 2,2,2-trifluoroethyl, formyl and hydroxyalkyl groups, alkoxyalkyl groups and hydroxyalkoxyalkyl groups wherein the alkyl moieties contain from 1 to 4 carbon atoms.

7. (Amended) A compound according to [any one of]claim[s] 1[to 3] wherein R⁴ and R⁵ independently represent hydrogen, a C₁-C₄ alkyl group which is unsubstituted or substituted by a hydroxy or dimethyl amino group, a propynyl group or an amidino group.


8. (Amended) A compound according to [any one of]claim[s] 1[to 3] wherein R⁴ is hydrogen or a C₁-C₄ alkyl group and R⁵ represents a group of formula



wherein n is 0, 1, 2 or 3 and R⁷ is a pyridyl, piperidyl, piperazinyl, morpholinyl, triazolyl, tetrazolyl, pyrrolidinyl, 1-ethylaminocyclohex-1-yl, 1-diethylaminocyclohex-1-yl, 1-ethylaminocyclohept-1-yl, 1-diethylaminocyclohept-1-yl, 3,4-dimethoxyphenyl, 1-methyl-4-phenylpiperidin-4-yl, imidazolyl, 1-methylpiperid-4-yl, tetrahydrofuranyl, 2,2,6,6-tetramethylpiperid-4-yl, 4-hydroxypiperid-4-yl, 1-acetamidocyclohept-1-yl, 1-methyl-3-azetidiny or 4-methylpiperazin-1-yl group.

9. (Amended) A compound according to [any one of] claim[s] 1[to 8] characterised in that it has an IC₅₀ value for the inhibition of PDE 5 of less than 30 nM.

11. (Amended) A process for preparing a compound as defined in [any one of] claim[s] 1[to 10] which process comprises reacting a hydrazinopurine derivative of formula (II)




(II)

wherein R², R³, R⁴ and R⁵ are as defined in [any one of] claim[s] 1[to 10], with a carboxylic acid of the general formula (III):




wherein R¹ is as defined in [any one of] claim[s] 1[to 10], or a reactive derivative thereof optionally in the presence of a polar aprotic solvent.

18. (Amended) A process for preparing a compound as defined in [any one of] claim[s] 1[to 10] which process comprises reacting a phenylxanthine of formula (IX):




(IX)

wherein R¹, R² and R³ are as defined in [any one of]claim[s] 1[to 10], with chlorosulphonic acid so as to obtain the sulphonyl chloride of formula (X):



(X)

wherein R¹, R² and R³ are as defined in [any one of]claim[s] 1[to 10], and reacting the sulphonyl chloride of formula (X) with an amine of formula (VIII):



(VIII)

wherein R⁴ and R⁵ are as defined in [any one of]claim[s] 1[to 10].

20. (Amended) A pharmaceutical composition comprising as an active ingredient, at least one compound as defined in [any one of]claim[s] 1[to 10] or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

10057647.012502